TITRATION OF LIVE MEASLES AND SMALLPOX VACCINES BY JET INOCULATION OF SUSCEPTIBLE CHILDREN.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to N G ROGERS.
Explore the source record for details and available documents.
Experience so far with the Enders B-level Edmonston strain of live attenuated measles vaccine has been principally with children in the USA in whom natural measles carries a low mortality. Measles is associated with an appreciably higher mortality rate in developing countries; in Upper Volta, climate, nutritional status, degree of parasitic infestation and concurrent infections may contribute to this. The present report summarizes a pilot study in Ouagadougou, Upper Volta, designed to obtain information on the response of Volta children to Enders vaccine and to determine the feasibility of using this vaccine on a large scale.The observations indicate that Volta children, despite the hazards of natural measles, respond in essentially the same manner to live vaccine given alone or with gamma-globulin as do children in other areas. The febrile reactions which characterize infection with the attenuated measles virus were of insufficient importance to warrant the concurrent use of gamma-globulin in a forthcoming mass measles vaccination campaign in Upper Volta.
An earlier study established that Upper Volta children respond to vaccination with the Enders live attenuated measles strain in the same general fashion as do children in the USA. The present report describes a second pilot project carried out in Ouagadougou, Upper Volta. During this investigation various mixtures of live measles, smallpox and 17D yellow fever vaccines were introduced into susceptible infants by jet injection. Combining the attenuated virus vaccines did not alter or accentuate the characteristic clinical reactions elicited by the individual components, nor was there evidence of significant immunological interference. From this experience it is concluded that combined vaccination with these agents may be safely and effectively employed in larger programmes as the need dictates.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.